150 related articles for article (PubMed ID: 25734632)
1. Genetics: Myeloproliferative neoplasms—order of mutations counts!
Hutchinson L
Nat Rev Clin Oncol; 2015 Apr; 12(4):187. PubMed ID: 25734632
[No Abstract] [Full Text] [Related]
2. Effect of mutation order on myeloproliferative neoplasms.
Delhommeau F
N Engl J Med; 2015 May; 372(19):1865. PubMed ID: 25946290
[No Abstract] [Full Text] [Related]
3. Effect of mutation order on myeloproliferative neoplasms.
Kent DG; Ortmann CA; Green AR
N Engl J Med; 2015 May; 372(19):1865-6. PubMed ID: 25946289
[No Abstract] [Full Text] [Related]
4. Tumorigenesis: Order matters.
Seton-Rogers S
Nat Rev Genet; 2015 Apr; 16(4):193. PubMed ID: 25783446
[No Abstract] [Full Text] [Related]
5. Tumorigenesis: Order matters.
Seton-Rogers S
Nat Rev Cancer; 2015 Apr; 15(4):196-7. PubMed ID: 25740421
[No Abstract] [Full Text] [Related]
6. Cancer evolution constrained by mutation order.
Swanton C
N Engl J Med; 2015 Feb; 372(7):661-3. PubMed ID: 25671259
[No Abstract] [Full Text] [Related]
7. A common genetic mechanism in malignant bone marrow diseases.
Levine RL; Carroll M
N Engl J Med; 2009 May; 360(22):2355-7. PubMed ID: 19474434
[No Abstract] [Full Text] [Related]
8. TET2 loss, a rescue of JAK2V617F HSCs.
Vainchenker W; Plo I
Blood; 2015 Jan; 125(2):212-3. PubMed ID: 25573967
[TBL] [Abstract][Full Text] [Related]
9. Dynamics of JAK2 V617F allele burden of CD34+ haematopoietic progenitor cells in patients treated with ruxolitinib.
Angona A; Alvarez-Larrán A; Bellosillo B; Longarón R; Fernández-Rodríguez C; Besses C
Br J Haematol; 2016 Feb; 172(4):639-42. PubMed ID: 26115187
[No Abstract] [Full Text] [Related]
10. Cytogenetic correlates of TET2 mutations in 199 patients with myeloproliferative neoplasms.
Hussein K; Abdel-Wahab O; Lasho TL; Van Dyke DL; Levine RL; Hanson CA; Pardanani A; Tefferi A
Am J Hematol; 2010 Jan; 85(1):81-3. PubMed ID: 19957346
[No Abstract] [Full Text] [Related]
11. Clonogenic versus morphogenic mutations in myeloid neoplasms: chronologic observations in a U2AF1, TET2, CSF3R and JAK2 'co-mutated' myeloproliferative neoplasm suggest a hierarchical order of mutations and potential predictive value for kinase inhibitor treatment response.
Gerlach MM; Lundberg P; Halter J; Arranto C; Wenzel F; Dirnhofer S; Tzankov A
Leuk Lymphoma; 2018 Aug; 59(8):1994-1997. PubMed ID: 29199511
[No Abstract] [Full Text] [Related]
12. Gene mutation order affects cancer behaviour.
Bagcchi S
Lancet Oncol; 2015 Mar; 16(3):e112. PubMed ID: 25704438
[No Abstract] [Full Text] [Related]
13. [Molecular biology and new drug therapy for myeloproliferative neoplasm].
Kitanaka A; Shide K; Shimoda K
Rinsho Ketsueki; 2013 Oct; 54(10):1697-703. PubMed ID: 24064819
[No Abstract] [Full Text] [Related]
14. The JAK2V617F mutation: no impact on circulating hematopoietic progenitors in myeloproliferative disorders.
Wappl M; Jaeger E; Kusec R; Schwarzinger I; Geissler K; Oehler L
Ann Hematol; 2008 Jun; 87(6):509-11. PubMed ID: 18180923
[No Abstract] [Full Text] [Related]
15. Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms.
Kosmider O; Gelsi-Boyer V; Slama L; Dreyfus F; Beyne-Rauzy O; Quesnel B; Hunault-Berger M; Slama B; Vey N; Lacombe C; Solary E; Birnbaum D; Bernard OA; Fontenay M
Leukemia; 2010 May; 24(5):1094-6. PubMed ID: 20376084
[No Abstract] [Full Text] [Related]
16. Analyses of TET2 mutations in post-myeloproliferative neoplasm acute myeloid leukemias.
Couronné L; Lippert E; Andrieux J; Kosmider O; Radford-Weiss I; Penther D; Dastugue N; Mugneret F; Lafage M; Gachard N; Nadal N; Bernard OA; Nguyen-Khac F
Leukemia; 2010 Jan; 24(1):201-3. PubMed ID: 19710701
[No Abstract] [Full Text] [Related]
17. The impact of JAK2 non-receptor tyrosine kinase mutation on the mobilization of hematopoietic stem cells into peripheral blood of patients with Philadelphia chromosome-negative myeloproliferative disorders.
Kannim S; Auewarakul CU
Int J Cancer; 2009 Aug; 125(4):988-90. PubMed ID: 19462461
[No Abstract] [Full Text] [Related]
18. Distinct effects of concomitant Jak2V617F expression and Tet2 loss in mice promote disease progression in myeloproliferative neoplasms.
Chen E; Schneider RK; Breyfogle LJ; Rosen EA; Poveromo L; Elf S; Ko A; Brumme K; Levine R; Ebert BL; Mullally A
Blood; 2015 Jan; 125(2):327-35. PubMed ID: 25281607
[TBL] [Abstract][Full Text] [Related]
19. Advances in the understanding and management of myeloproliferative disorders.
Skoda R
Eur J Haematol Suppl; 2007 Oct; (68):2-4. PubMed ID: 17727556
[No Abstract] [Full Text] [Related]
20. JAK2 V617F: a single mutation in the myeloproliferative group of disorders.
McLornan D; Percy M; McMullin MF
Ulster Med J; 2006 May; 75(2):112-9. PubMed ID: 16755940
[No Abstract] [Full Text] [Related]
[Next] [New Search]
